Global Diabetic Retinopathy Market Size, Share & Industry Trends Analysis Report By Type (Proliferative and Diabetic Macular Edema (DME)), By Treatment Type, By Regional Outlook and Forecast, 2021 - 2027

The Global Diabetic Retinopathy Market size is expected to reach $7.7 billion by 2027, rising at a market growth of 11.3% CAGR during the forecast period.

Diabetic retinopathy is a critical medical disorder that affects the eyes as a result of diabetes or inefficient insulin level in the blood of the patient. Impairment to blood vessels of the light-sensitive tissue of the retina is the main cause of diabetic retinopathy. In addition, blurred vision, dark or empty spots in the vision, fluctuating vision, poor color identification, and vision loss are the most typical symptoms of this disorder. A high sugar level in the blood causes blockage of the retina's small blood capillaries, impeding blood flow. Advanced cases of diabetic retinopathy require laser therapy or surgical operations. Mild-to-moderate instances of diabetic retinopathy can be cured with appropriate diabetes management.

Diabetic retinopathy may cause no symptoms or just minor vision abnormalities in the initial stages, however, it can result in blindness in advance stages. Anyone with type 1 or type 2 diabetes can develop the illness. The longer a person has diabetes, the more likely they are to develop ocular complications due to poorly regulated blood sugar levels. Diabetic retinopathy can progress to diabetic retinal detachment, macular edema, and neovascular glaucoma, among other serious eye disorders.

Diabetic retinopathy can also mutate to proliferative diabetic retinopathy, which is a more severe form of the disorder. Affected blood vessels close off in this type, leading the retina to develop new, dysfunctional blood vessels. These new blood vessels are fragile, and they may leak into the clear, jellylike fluid that fills the center of the eye of the patient. Non-proliferative diabetic retinopathy, NPDR, is a kind of diabetic retinopathy in which symptoms are minimal or absent. New blood vessels are weakened or stop forming in this more prevalent form of diabetic retinopathy. The membranes of the blood vessels in the retina deteriorate when a patient suffers NPDR. Small bulges emerge from the smaller vessels' walls, occasionally blood and seeping fluid into the retina. Larger retinal vessels may also begin to dilate and their size becomes irregular.

COVID-19 Impact Analysis

The COVID-19 pandemic caused a severe impact to various economies all over the world. Several businesses were significantly devastated as a result of the outbreak of the COVID-19 infection. In addition, the governments of several countries were forced to impose lockdowns in their nations. As a result, the manufacturing units of numerous goods were temporarily shut. Moreover, these lockdowns also caused a major disruption in the supply chain of various goods. Further, the COVID-19 led the worldwide healthcare industry to a significant failure due to the shortage of beds and oxygen in hospitals. The outbreak of COVID-19 all over the world has placed healthcare workflows in a disarray. Various industries, including numerous sub-domains of healthcare, have been forced to temporarily close their units because of the rising cases of infection.

Market driving Factors:

Rising number of diabetic patients

Diabetes is considered as the major origin of diabetic retinopathy. Therefore, an increase in the number of patients that are suffering from diabetes would directly increase the demand for diabetic retinopathy treatments. In addition, there is a significant rise in the number of patients with diabetes, due to which, the requirement of diabetic retinopathy treatment is continuously increasing. There is a significant number of people that are concerned about the damage that can be caused to their eyes by the occurrence of the diabetic retinopathy. The diabetic retinopathy market is expected to grow due to an increase in diabetes prevalence around the world. According to the National Center for Biotechnology Information, Diabetic retinopathy affected 126 million people in 2010, and it is expected to affect more than 191 million people by 2030.

Increasing geriatric population all over the world

Instances of the diabetic retinopathy are more common in geriatric people. The prevalence of this disorder is found to be more robust in people that are aging above 60. Moreover, the number of elderly people is becoming significant and accounts for a substantial share of the population in nearly every country, affecting several aspects of society, including financial markets and labor, demand for goods and services, like housing, transportation, as well as social protection, along with family structures and intergenerational ties. According to the United Nations Organization, the population of elderly people all over the world is expected to become more than double throughout the next three decades, reaching 1.5 billion by 2050.

Marketing Restraining Factor:

Lack of healthcare facilities in developing and under-developed economies

People residing in poor countries have lesser access to healthcare facilities than wealthy people, while the poor people have lesser access to healthcare services inside their own countries. In contrast, poor people in low- and Middle-income countries, or LMICs, are continuously disadvantaged in several aspects of access as well as their determinants. Moreover, the healthcare sector in the least developed countries is poorly underfunded, and a vast majority of these countries are unable to provide basic and fundamental healthcare services to their citizens. This problem is most prevalent in under-developed and developing countries, where government's investments on public security is increasing at the cost of healthcare expenditure.

Type Outlook

Based on Type, the market is segmented into Proliferative and Diabetic Macular Edema (DME). In 2020, the diabetic macular edema segment witnessed a substantial revenue share of the diabetic retinopathy market. Diabetic macular edema, or DME, is an eye disorder that can affect people with type 1 as well as type 2 diabetes. High blood sugar levels that persist over time due to inadequate glucose regulation can harm small blood vessels inside the body, including the eyes. Diabetic retinopathy is a disorder that causes vision loss by damaging the blood vessels inside the retina. Fluid can leak into the fovea, which is the area of the eye where acute, straight-ahead vision occurs if left untreated. The fluid causes the macula to swell, causing vision to become blurry.

Treatment Type Outlook

Based on Treatment Type, the market is segmented into Anti VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy. In 2020, the anti VEGF drugs segment procured the largest revenue share of the diabetic retinopathy market. Anti-VEGF medications are a class of drugs that prevent the growth of new blood vessel and edema. These medications can be used to treat a variety of eye disorders that produce new blood vessel growth or swelling underneath the macular area of the retina. The rising growth of this segment is owing to the reliability and effectiveness of this class of drugs. A significant number of healthcare facilities are leveraging these drugs in order to treat diabetic retinopathy.

Diabetic Retinopathy Market Report Coverage

Report Attribute	Details
Market size value in 2020	USD 3.9 Billion
Market size forecast in 2027	USD 7.7 Billion
Base Year	2020
Historical Period	2017 to 2019
Forecast Period	2021 to 2027
Revenue Growth Rate	CAGR of 11.3% from 2021 to 2027
Number of Pages	156
Number of Tables	260
Report coverage	Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling
Segments covered	Type, Treatment Type, Region
Country scope	US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers	Rising number of diabetic patients Increasing geriatric population all over the world
Restraints	Lack of healthcare facilities in developing and under-developed economies

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2020, North America procured the largest revenue share of the diabetic retinopathy market. The increasing growth of this segment is attributed to the higher and rapidly increasing frequency of diabetic retinopathy in this region, combined with well-established healthcare infrastructure along with increasing government measures to raise awareness. These government initiatives would make it easier for people to get examined for diabetic retinopathy. Moreover, North America is one of the most advanced regions in terms of technology. The adoption of various latest cutting-edge technologies across the region is increasing in several sectors in the region.

Free Valuable Insights: Global Diabetic Retinopathy Market size to reach USD 7.7 Billion by 2027

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (Abbvie, Inc.), Bayer AG, Alimera Sciences, Inc., Novartis AG, Pfizer, Inc., F-Hoffmann-La Roche Ltd., Ampio Pharmaceuticals-us, KOWA CO., LTD., Regeneron Pharmaceuticals, Inc., and Bausch Health Companies, Inc.

Recent Strategies Deployed in Diabetic Retinopathy Market

• Feb-2022: Alimera Sciences expanded its geographical footprint in Spain with the launch of ILUVIEN. Through this geographical expansion, the company aimed to provide treatment for non-infectious posterior uveitis to its customers across Spain.
• Jan-2022: Roche received the US FDA approval for Vabysmo. The new product aimed to treat neovascular or wet age-related macular degeneration along with diabetic macular edema.
• Oct-2021: Roche got the US FDA approval for its Susvimo 100 mg/mL. The new product would be available for intravitreal use through the ocular implant for the diagnosis of patients with neovascular or wet age-related macular degeneration.
• Oct-2021: Bausch along with Lomb and Clearside Biomedical received the US FDA approval for XIPERE. The new product would be available for suprachoroidal use in order to treat macular edema related to uveitis.
• Sep-2021: AbbVie partnered with REGENXBIO, a leading clinical-stage biotechnology company. Following this partnership, the companies would jointly develop and commercialize RGX-314 intending to offer a potential one-time gene therapy to cure diabetic retinopathy, wet age-related macular degeneration, and other chronic retinal disorders.
• May-2021: Bausch came into a strategic multi-year agreement with SIFI, a leader in international ophthalmic. Following this agreement, Bausch would support SIFI in commercializing its innovative products for the treatment of ophthalmic disorders across Russia.
• Apr-2021: Alimera Sciences entered into an exclusive license agreement with Ocumension Therapeutics, a Chinese ophthalmology platform company. Following this acquisition, Alimera would deliver Alimera’s 0.19mg fluocinolone acetonide intravitreal implant to Ocumension in order to focus on its vision geographic expansion.
• Mar-2021: Roche signed a multi-year research collaboration and licensing agreement with SemaThera, a biotechnology company. This collaboration aimed to develop a new lineup of biologicals under the umbrella of SemaThera to treat diabetic retinopathy as well as other ischemic retinal diseases.
• Dec-2020: Alimera Sciences expanded its geographical footprint with the launch of ILUVIEN in the Netherlands. This geographical expansion would complement the company's strategy to avail ILUVIEN to more patients and physicians in various geographies.
• Sep-2020: Alimera Sciences entered into a distribution agreement with Medis Pharmaceutical Company, the largest India-based Pharmaceutical Company. Through this agreement, Alimera aimed to expand its geographical footprint in the Czech Republic and Austria with the launch of ILUVIEN in the countries.
• Sep-2020: Bayer received Drugs Controller General of India approval for its novel indication for intravitreal Aflibercept injection solution. This approval aimed to accelerate the treatment of Diabetic Macular Edema with a new injection solution, which is available for intravitreal use in India.
• May-2019: Regeneron Pharmaceuticals received the US FDA approval for EYLEA injection. The new product would be leveraged for the treatment of all stages of diabetic retinopathy to minimize the risk of blindness.

Scope of the Study

Market Segments Covered in the Report:

By Type

• Proliferative
• Diabetic Macular Edema (DME)

By Treatment Type

• Anti VEGF Drug
• Steroid Implants
• Laser Surgeries
• Vitrectomy

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Allergan PLC (Abbvie, Inc.)
• Bayer AG
• Alimera Sciences, Inc.
• Novartis AG
• Pfizer, Inc.
• F-Hoffmann-La Roche Ltd.
• Ampio Pharmaceuticals-us
• KOWA CO., LTD.
• Regeneron Pharmaceuticals, Inc.
• Bausch Health Companies, Inc.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Diabetic Retinopathy Market, by Type
1.4.2 Global Diabetic Retinopathy Market, by Treatment Type
1.4.3 Global Diabetic Retinopathy Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Strategies Deployed in Diabetic Retinopathy Market

Chapter 4. Global Diabetic Retinopathy Market by Type
4.1 Global Proliferative Market by Region
4.2 Global Diabetic Macular Edema (DME) Market by Region

Chapter 5. Global Diabetic Retinopathy Market by Treatment Type
5.1 Global Anti VEGF Drug Market by Region
5.2 Global Steroid Implants Market by Region
5.3 Global Laser Surgeries Market by Region
5.4 Global Vitrectomy Market by Region

Chapter 6. Global Diabetic Retinopathy Market by Region
6.1 North America Diabetic Retinopathy Market
6.1.1 North America Diabetic Retinopathy Market by Type
6.1.1.1 North America Proliferative Market by Country
6.1.1.2 North America Diabetic Macular Edema (DME) Market by Country
6.1.2 North America Diabetic Retinopathy Market by Treatment Type
6.1.2.1 North America Anti VEGF Drug Market by Country
6.1.2.2 North America Steroid Implants Market by Country
6.1.2.3 North America Laser Surgeries Market by Country
6.1.2.4 North America Vitrectomy Market by Country
6.1.3 North America Diabetic Retinopathy Market by Country
6.1.3.1 US Diabetic Retinopathy Market
6.1.3.1.1 US Diabetic Retinopathy Market by Type
6.1.3.1.2 US Diabetic Retinopathy Market by Treatment Type
6.1.3.2 Canada Diabetic Retinopathy Market
6.1.3.2.1 Canada Diabetic Retinopathy Market by Type
6.1.3.2.2 Canada Diabetic Retinopathy Market by Treatment Type
6.1.3.3 Mexico Diabetic Retinopathy Market
6.1.3.3.1 Mexico Diabetic Retinopathy Market by Type
6.1.3.3.2 Mexico Diabetic Retinopathy Market by Treatment Type
6.1.3.4 Rest of North America Diabetic Retinopathy Market
6.1.3.4.1 Rest of North America Diabetic Retinopathy Market by Type
6.1.3.4.2 Rest of North America Diabetic Retinopathy Market by Treatment Type
6.2 Europe Diabetic Retinopathy Market
6.2.1 Europe Diabetic Retinopathy Market by Type
6.2.1.1 Europe Proliferative Market by Country
6.2.1.2 Europe Diabetic Macular Edema (DME) Market by Country
6.2.2 Europe Diabetic Retinopathy Market by Treatment Type
6.2.2.1 Europe Anti VEGF Drug Market by Country
6.2.2.2 Europe Steroid Implants Market by Country
6.2.2.3 Europe Laser Surgeries Market by Country
6.2.2.4 Europe Vitrectomy Market by Country
6.2.3 Europe Diabetic Retinopathy Market by Country
6.2.3.1 Germany Diabetic Retinopathy Market
6.2.3.1.1 Germany Diabetic Retinopathy Market by Type
6.2.3.1.2 Germany Diabetic Retinopathy Market by Treatment Type
6.2.3.2 UK Diabetic Retinopathy Market
6.2.3.2.1 UK Diabetic Retinopathy Market by Type
6.2.3.2.2 UK Diabetic Retinopathy Market by Treatment Type
6.2.3.3 France Diabetic Retinopathy Market
6.2.3.3.1 France Diabetic Retinopathy Market by Type
6.2.3.3.2 France Diabetic Retinopathy Market by Treatment Type
6.2.3.4 Russia Diabetic Retinopathy Market
6.2.3.4.1 Russia Diabetic Retinopathy Market by Type
6.2.3.4.2 Russia Diabetic Retinopathy Market by Treatment Type
6.2.3.5 Spain Diabetic Retinopathy Market
6.2.3.5.1 Spain Diabetic Retinopathy Market by Type
6.2.3.5.2 Spain Diabetic Retinopathy Market by Treatment Type
6.2.3.6 Italy Diabetic Retinopathy Market
6.2.3.6.1 Italy Diabetic Retinopathy Market by Type
6.2.3.6.2 Italy Diabetic Retinopathy Market by Treatment Type
6.2.3.7 Rest of Europe Diabetic Retinopathy Market
6.2.3.7.1 Rest of Europe Diabetic Retinopathy Market by Type
6.2.3.7.2 Rest of Europe Diabetic Retinopathy Market by Treatment Type
6.3 Asia Pacific Diabetic Retinopathy Market
6.3.1 Asia Pacific Diabetic Retinopathy Market by Type
6.3.1.1 Asia Pacific Proliferative Market by Country
6.3.1.2 Asia Pacific Diabetic Macular Edema (DME) Market by Country
6.3.2 Asia Pacific Diabetic Retinopathy Market by Treatment Type
6.3.2.1 Asia Pacific Anti VEGF Drug Market by Country
6.3.2.2 Asia Pacific Steroid Implants Market by Country
6.3.2.3 Asia Pacific Laser Surgeries Market by Country
6.3.2.4 Asia Pacific Vitrectomy Market by Country
6.3.3 Asia Pacific Diabetic Retinopathy Market by Country
6.3.3.1 China Diabetic Retinopathy Market
6.3.3.1.1 China Diabetic Retinopathy Market by Type
6.3.3.1.2 China Diabetic Retinopathy Market by Treatment Type
6.3.3.2 Japan Diabetic Retinopathy Market
6.3.3.2.1 Japan Diabetic Retinopathy Market by Type
6.3.3.2.2 Japan Diabetic Retinopathy Market by Treatment Type
6.3.3.3 India Diabetic Retinopathy Market
6.3.3.3.1 India Diabetic Retinopathy Market by Type
6.3.3.3.2 India Diabetic Retinopathy Market by Treatment Type
6.3.3.4 South Korea Diabetic Retinopathy Market
6.3.3.4.1 South Korea Diabetic Retinopathy Market by Type
6.3.3.4.2 South Korea Diabetic Retinopathy Market by Treatment Type
6.3.3.5 Singapore Diabetic Retinopathy Market
6.3.3.5.1 Singapore Diabetic Retinopathy Market by Type
6.3.3.5.2 Singapore Diabetic Retinopathy Market by Treatment Type
6.3.3.6 Malaysia Diabetic Retinopathy Market
6.3.3.6.1 Malaysia Diabetic Retinopathy Market by Type
6.3.3.6.2 Malaysia Diabetic Retinopathy Market by Treatment Type
6.3.3.7 Rest of Asia Pacific Diabetic Retinopathy Market
6.3.3.7.1 Rest of Asia Pacific Diabetic Retinopathy Market by Type
6.3.3.7.2 Rest of Asia Pacific Diabetic Retinopathy Market by Treatment Type
6.4 LAMEA Diabetic Retinopathy Market
6.4.1 LAMEA Diabetic Retinopathy Market by Type
6.4.1.1 LAMEA Proliferative Market by Country
6.4.1.2 LAMEA Diabetic Macular Edema (DME) Market by Country
6.4.2 LAMEA Diabetic Retinopathy Market by Treatment Type
6.4.2.1 LAMEA Anti VEGF Drug Market by Country
6.4.2.2 LAMEA Steroid Implants Market by Country
6.4.2.3 LAMEA Laser Surgeries Market by Country
6.4.2.4 LAMEA Vitrectomy Market by Country
6.4.3 LAMEA Diabetic Retinopathy Market by Country
6.4.3.1 Brazil Diabetic Retinopathy Market
6.4.3.1.1 Brazil Diabetic Retinopathy Market by Type
6.4.3.1.2 Brazil Diabetic Retinopathy Market by Treatment Type
6.4.3.2 Argentina Diabetic Retinopathy Market
6.4.3.2.1 Argentina Diabetic Retinopathy Market by Type
6.4.3.2.2 Argentina Diabetic Retinopathy Market by Treatment Type
6.4.3.3 UAE Diabetic Retinopathy Market
6.4.3.3.1 UAE Diabetic Retinopathy Market by Type
6.4.3.3.2 UAE Diabetic Retinopathy Market by Treatment Type
6.4.3.4 Saudi Arabia Diabetic Retinopathy Market
6.4.3.4.1 Saudi Arabia Diabetic Retinopathy Market by Type
6.4.3.4.2 Saudi Arabia Diabetic Retinopathy Market by Treatment Type
6.4.3.5 South Africa Diabetic Retinopathy Market
6.4.3.5.1 South Africa Diabetic Retinopathy Market by Type
6.4.3.5.2 South Africa Diabetic Retinopathy Market by Treatment Type
6.4.3.6 Nigeria Diabetic Retinopathy Market
6.4.3.6.1 Nigeria Diabetic Retinopathy Market by Type
6.4.3.6.2 Nigeria Diabetic Retinopathy Market by Treatment Type
6.4.3.7 Rest of LAMEA Diabetic Retinopathy Market
6.4.3.7.1 Rest of LAMEA Diabetic Retinopathy Market by Type
6.4.3.7.2 Rest of LAMEA Diabetic Retinopathy Market by Treatment Type

Chapter 7. Company Profiles
7.1 Alimera Sciences, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, Collaborations, and Agreements:
7.1.5.2 Geographical Expansions:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Approvals and Trials:
7.3 Bausch Health Companies, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.3.5.2 Approvals and Trials:
7.4 Bayer AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Allergan PLC (AbbVie, Inc.)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Regeneron Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expense
7.8.3.1 Approvals and Trials:
7.9 Ampio Pharmaceuticals, Inc.
7.9.1 Company Overview
7.10. Kowa Company, Ltd.
7.10.1 Company Overview

TABLE 1 Global Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 2 Global Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 3 Global Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 4 Global Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 5 Global Proliferative Market by Region, 2017 - 2020, USD Million
TABLE 6 Global Proliferative Market by Region, 2021 - 2027, USD Million
TABLE 7 Global Diabetic Macular Edema (DME) Market by Region, 2017 - 2020, USD Million
TABLE 8 Global Diabetic Macular Edema (DME) Market by Region, 2021 - 2027, USD Million
TABLE 9 Global Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 10 Global Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 11 Global Anti VEGF Drug Market by Region, 2017 - 2020, USD Million
TABLE 12 Global Anti VEGF Drug Market by Region, 2021 - 2027, USD Million
TABLE 13 Global Steroid Implants Market by Region, 2017 - 2020, USD Million
TABLE 14 Global Steroid Implants Market by Region, 2021 - 2027, USD Million
TABLE 15 Global Laser Surgeries Market by Region, 2017 - 2020, USD Million
TABLE 16 Global Laser Surgeries Market by Region, 2021 - 2027, USD Million
TABLE 17 Global Vitrectomy Market by Region, 2017 - 2020, USD Million
TABLE 18 Global Vitrectomy Market by Region, 2021 - 2027, USD Million
TABLE 19 Global Diabetic Retinopathy Market by Region, 2017 - 2020, USD Million
TABLE 20 Global Diabetic Retinopathy Market by Region, 2021 - 2027, USD Million
TABLE 21 North America Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 22 North America Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 23 North America Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 24 North America Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 25 North America Proliferative Market by Country, 2017 - 2020, USD Million
TABLE 26 North America Proliferative Market by Country, 2021 - 2027, USD Million
TABLE 27 North America Diabetic Macular Edema (DME) Market by Country, 2017 - 2020, USD Million
TABLE 28 North America Diabetic Macular Edema (DME) Market by Country, 2021 - 2027, USD Million
TABLE 29 North America Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 30 North America Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 31 North America Anti VEGF Drug Market by Country, 2017 - 2020, USD Million
TABLE 32 North America Anti VEGF Drug Market by Country, 2021 - 2027, USD Million
TABLE 33 North America Steroid Implants Market by Country, 2017 - 2020, USD Million
TABLE 34 North America Steroid Implants Market by Country, 2021 - 2027, USD Million
TABLE 35 North America Laser Surgeries Market by Country, 2017 - 2020, USD Million
TABLE 36 North America Laser Surgeries Market by Country, 2021 - 2027, USD Million
TABLE 37 North America Vitrectomy Market by Country, 2017 - 2020, USD Million
TABLE 38 North America Vitrectomy Market by Country, 2021 - 2027, USD Million
TABLE 39 North America Diabetic Retinopathy Market by Country, 2017 - 2020, USD Million
TABLE 40 North America Diabetic Retinopathy Market by Country, 2021 - 2027, USD Million
TABLE 41 US Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 42 US Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 43 US Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 44 US Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 45 US Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 46 US Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 47 Canada Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 48 Canada Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 49 Canada Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 50 Canada Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 51 Canada Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 52 Canada Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 53 Mexico Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 54 Mexico Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 55 Mexico Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 56 Mexico Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 57 Mexico Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 58 Mexico Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 59 Rest of North America Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 60 Rest of North America Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 61 Rest of North America Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 62 Rest of North America Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 63 Rest of North America Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 64 Rest of North America Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 65 Europe Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 66 Europe Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 67 Europe Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 68 Europe Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 69 Europe Proliferative Market by Country, 2017 - 2020, USD Million
TABLE 70 Europe Proliferative Market by Country, 2021 - 2027, USD Million
TABLE 71 Europe Diabetic Macular Edema (DME) Market by Country, 2017 - 2020, USD Million
TABLE 72 Europe Diabetic Macular Edema (DME) Market by Country, 2021 - 2027, USD Million
TABLE 73 Europe Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 74 Europe Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 75 Europe Anti VEGF Drug Market by Country, 2017 - 2020, USD Million
TABLE 76 Europe Anti VEGF Drug Market by Country, 2021 - 2027, USD Million
TABLE 77 Europe Steroid Implants Market by Country, 2017 - 2020, USD Million
TABLE 78 Europe Steroid Implants Market by Country, 2021 - 2027, USD Million
TABLE 79 Europe Laser Surgeries Market by Country, 2017 - 2020, USD Million
TABLE 80 Europe Laser Surgeries Market by Country, 2021 - 2027, USD Million
TABLE 81 Europe Vitrectomy Market by Country, 2017 - 2020, USD Million
TABLE 82 Europe Vitrectomy Market by Country, 2021 - 2027, USD Million
TABLE 83 Europe Diabetic Retinopathy Market by Country, 2017 - 2020, USD Million
TABLE 84 Europe Diabetic Retinopathy Market by Country, 2021 - 2027, USD Million
TABLE 85 Germany Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 86 Germany Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 87 Germany Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 88 Germany Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 89 Germany Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 90 Germany Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 91 UK Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 92 UK Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 93 UK Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 94 UK Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 95 UK Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 96 UK Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 97 France Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 98 France Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 99 France Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 100 France Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 101 France Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 102 France Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 103 Russia Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 104 Russia Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 105 Russia Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 106 Russia Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 107 Russia Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 108 Russia Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 109 Spain Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 110 Spain Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 111 Spain Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 112 Spain Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 113 Spain Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 114 Spain Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 115 Italy Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 116 Italy Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 117 Italy Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 118 Italy Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 119 Italy Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 120 Italy Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 121 Rest of Europe Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 122 Rest of Europe Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 123 Rest of Europe Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 124 Rest of Europe Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 125 Rest of Europe Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 126 Rest of Europe Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 127 Asia Pacific Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 128 Asia Pacific Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 129 Asia Pacific Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 130 Asia Pacific Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 131 Asia Pacific Proliferative Market by Country, 2017 - 2020, USD Million
TABLE 132 Asia Pacific Proliferative Market by Country, 2021 - 2027, USD Million
TABLE 133 Asia Pacific Diabetic Macular Edema (DME) Market by Country, 2017 - 2020, USD Million
TABLE 134 Asia Pacific Diabetic Macular Edema (DME) Market by Country, 2021 - 2027, USD Million
TABLE 135 Asia Pacific Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 136 Asia Pacific Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 137 Asia Pacific Anti VEGF Drug Market by Country, 2017 - 2020, USD Million
TABLE 138 Asia Pacific Anti VEGF Drug Market by Country, 2021 - 2027, USD Million
TABLE 139 Asia Pacific Steroid Implants Market by Country, 2017 - 2020, USD Million
TABLE 140 Asia Pacific Steroid Implants Market by Country, 2021 - 2027, USD Million
TABLE 141 Asia Pacific Laser Surgeries Market by Country, 2017 - 2020, USD Million
TABLE 142 Asia Pacific Laser Surgeries Market by Country, 2021 - 2027, USD Million
TABLE 143 Asia Pacific Vitrectomy Market by Country, 2017 - 2020, USD Million
TABLE 144 Asia Pacific Vitrectomy Market by Country, 2021 - 2027, USD Million
TABLE 145 Asia Pacific Diabetic Retinopathy Market by Country, 2017 - 2020, USD Million
TABLE 146 Asia Pacific Diabetic Retinopathy Market by Country, 2021 - 2027, USD Million
TABLE 147 China Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 148 China Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 149 China Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 150 China Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 151 China Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 152 China Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 153 Japan Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 154 Japan Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 155 Japan Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 156 Japan Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 157 Japan Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 158 Japan Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 159 India Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 160 India Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 161 India Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 162 India Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 163 India Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 164 India Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 165 South Korea Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 166 South Korea Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 167 South Korea Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 168 South Korea Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 169 South Korea Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 170 South Korea Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 171 Singapore Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 172 Singapore Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 173 Singapore Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 174 Singapore Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 175 Singapore Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 176 Singapore Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 177 Malaysia Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 178 Malaysia Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 179 Malaysia Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 180 Malaysia Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 181 Malaysia Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 182 Malaysia Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 183 Rest of Asia Pacific Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 184 Rest of Asia Pacific Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 185 Rest of Asia Pacific Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 186 Rest of Asia Pacific Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 187 Rest of Asia Pacific Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 188 Rest of Asia Pacific Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 189 LAMEA Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 190 LAMEA Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 191 LAMEA Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 192 LAMEA Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 193 LAMEA Proliferative Market by Country, 2017 - 2020, USD Million
TABLE 194 LAMEA Proliferative Market by Country, 2021 - 2027, USD Million
TABLE 195 LAMEA Diabetic Macular Edema (DME) Market by Country, 2017 - 2020, USD Million
TABLE 196 LAMEA Diabetic Macular Edema (DME) Market by Country, 2021 - 2027, USD Million
TABLE 197 LAMEA Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 198 LAMEA Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 199 LAMEA Anti VEGF Drug Market by Country, 2017 - 2020, USD Million
TABLE 200 LAMEA Anti VEGF Drug Market by Country, 2021 - 2027, USD Million
TABLE 201 LAMEA Steroid Implants Market by Country, 2017 - 2020, USD Million
TABLE 202 LAMEA Steroid Implants Market by Country, 2021 - 2027, USD Million
TABLE 203 LAMEA Laser Surgeries Market by Country, 2017 - 2020, USD Million
TABLE 204 LAMEA Laser Surgeries Market by Country, 2021 - 2027, USD Million
TABLE 205 LAMEA Vitrectomy Market by Country, 2017 - 2020, USD Million
TABLE 206 LAMEA Vitrectomy Market by Country, 2021 - 2027, USD Million
TABLE 207 LAMEA Diabetic Retinopathy Market by Country, 2017 - 2020, USD Million
TABLE 208 LAMEA Diabetic Retinopathy Market by Country, 2021 - 2027, USD Million
TABLE 209 Brazil Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 210 Brazil Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 211 Brazil Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 212 Brazil Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 213 Brazil Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 214 Brazil Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 215 Argentina Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 216 Argentina Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 217 Argentina Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 218 Argentina Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 219 Argentina Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 220 Argentina Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 221 UAE Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 222 UAE Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 223 UAE Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 224 UAE Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 225 UAE Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 226 UAE Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 227 Saudi Arabia Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 228 Saudi Arabia Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 229 Saudi Arabia Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 230 Saudi Arabia Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 231 Saudi Arabia Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 232 Saudi Arabia Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 233 South Africa Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 234 South Africa Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 235 South Africa Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 236 South Africa Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 237 South Africa Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 238 South Africa Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 239 Nigeria Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 240 Nigeria Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 241 Nigeria Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 242 Nigeria Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 243 Nigeria Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 244 Nigeria Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 245 Rest of LAMEA Diabetic Retinopathy Market, 2017 - 2020, USD Million
TABLE 246 Rest of LAMEA Diabetic Retinopathy Market, 2021 - 2027, USD Million
TABLE 247 Rest of LAMEA Diabetic Retinopathy Market by Type, 2017 - 2020, USD Million
TABLE 248 Rest of LAMEA Diabetic Retinopathy Market by Type, 2021 - 2027, USD Million
TABLE 249 Rest of LAMEA Diabetic Retinopathy Market by Treatment Type, 2017 - 2020, USD Million
TABLE 250 Rest of LAMEA Diabetic Retinopathy Market by Treatment Type, 2021 - 2027, USD Million
TABLE 251 Key Information – Alimera Sciences, Inc.
TABLE 252 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 253 key information – Bausch Health Companies, Inc.
TABLE 254 Key Information – Bayer AG
TABLE 255 Key Information – Pfizer, Inc.
TABLE 256 Key Information – Novartis AG
TABLE 257 Key Information – Allergan PLC
TABLE 258 Key Information – Regeneron Pharmaceuticals, Inc.
TABLE 259 Key Information – Ampio Pharmaceuticals, Inc.
TABLE 260 Key Information – Kowa Company, Ltd.

List of Figures
FIG 1 Methodology for the research
FIG 2 Global Diabetic Retinopathy Market Share by Type, 2020
FIG 3 Global Diabetic Retinopathy Market Share by Type, 2027
FIG 4 Global Diabetic Retinopathy Market by Type, 2017 - 2027, USD Million
FIG 5 Global Diabetic Retinopathy Market Share by Treatment Type, 2020
FIG 6 Global Diabetic Retinopathy Market Share by Treatment Type, 2027
FIG 7 Global Diabetic Retinopathy Market by Treatment Type, 2017 - 2027, USD Million
FIG 8 Global Diabetic Retinopathy Market Share by Region, 2020
FIG 9 Global Diabetic Retinopathy Market Share by Region, 2027
FIG 10 Global Diabetic Retinopathy Market by Region, 2017 - 2027, USD Million
FIG 11 Recent strategies and developments: Alimera Sciences, Inc.